Cagrilintide
Symbol Cg · MW 4409 Da
Long-acting amylin analog studied alongside semaglutide for weight loss.
- Discovered
- 2021
- Half-life
- 8 days
- Approval
- Investigational
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 4409 Da
- Half-life
- 8 days
- Discovered
- 2021
- Approval status
- Investigational
Reported effects
- Appetite suppression
- Satiety
- Synergy with GLP-1s
Overview
Cagrilintide is a long-acting amylin analog peptide being studied for weight management, appetite control, and obesity treatment. Amylin is a hormone involved in satiety, blood sugar regulation, and slowing gastric emptying, which helps promote a feeling of fullness after eating. Cagrilintide is often discussed alongside GLP-1 weight loss medications because it may complement appetite-regulating pathways. Its main purpose is to reduce hunger, improve satiety, and support lower calorie intake over time. As a modern weight loss peptide, Cagrilintide represents a newer class of metabolic peptides focused on appetite regulation rather than stimulant-based fat burning.
Evidence context
Cagrilintide evidence summary
Human clinical evidence
Human clinical evidence for Cagrilintide may be limited, investigational, region-specific, or unavailable in the local source data. Peptidic avoids treating reported effects as proven clinical outcomes.
Animal, preclinical, or formulation evidence
Cagrilintide may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Cagrilintide as Investigational. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Investigational research range: 0.3–4.5 mg
- Typical Frequency
- Once weekly
There is no established FDA-approved dosage for this peptide. This information is for educational reference only and should not be treated as medical guidance.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Cagrilintide.
Internal links
Related peptides
Frequently asked questions
What category is Cagrilintide in?
Cagrilintide is listed in the Weight Loss category on Peptidic.
What route is Cagrilintide associated with?
Cagrilintide is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Cagrilintide approved?
Peptidic lists the approval status for Cagrilintide as: Investigational. Approval details can vary by indication and jurisdiction.
Interested in Cagrilintide?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01